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Abstract The heterogeneous presentation and progression of
atrial fibrillation (AF) implicate the existence of different path-
ophysiological processes. Individualized diagnosis and thera-
py of the arrhythmogenic substrate underlying AF may be
required to improve treatment outcomes. Therefore, this
single-center study aims to identify the arrhythmogenic areas
underlying AF by intra-operative, high-resolution, multi-site
epicardial mapping in 600 patients with different heart dis-
eases. Participants are divided into 12 groups according to
the underlying heart diseases and presence of prior AF epi-
sodes.Mapping is performedwith a 192-electrode array for 5–
10 s during sinus rhythm and (induced) AF of the entire atrial
surface. Local activation times are converted into activation
and wave maps from which various electrophysiological pa-
rameters are derived. Postoperative cardiac rhythm registra-
tions and a 5-year follow-up will show the incidence of post-
operative and persistent AF. This project provides the first step
in the development of a tool for individual AF diagnosis and
treatment.
Keywords Atrial fibrillation . Epicardial mapping .
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Introduction
Atrial fibrillation (AF) is characterized by beat-to-beat chang-
es in the pattern of activation within the atria, unlike organized
arrhythmias such as atrial flutter and atrial tachycardia. This
chaotic nature poses a challenge with regard to understanding
the pathophysiology and effective treatment of AF as shown
by the frequent recurrences after AF therapy [1–4]. Due to the
limited knowledge about the mechanisms involved, each AF
patient is currently approached in the same manner. Based on
the symptomatology and a clinical assessment the arrhythmia
is either accepted or attempts are made to retain sinus rhythm
with non-selective treatment modalities. However, this ap-
proach does not take account of the diversity among AF pa-
tients. AF occurs, for example, in association withmitral valve
disease, hypertension, congenital heart disease, or cardiac sur-
gery, or in young or older patients without any comorbidity
(Blone AF^) [5, 6]. Furthermore, AF can have different clini-
cal manifestations including paroxysmal, persistent, or
longstanding persistent. On the structural level, the degree of
fibrotic tissue in AF patients demonstrated heterogeneity as
well and does not always predict the severity of the AF burden
[7]. Therefore, it is likely that the pathophysiological
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mechanisms may differ between patients with AF. If these can
be unraveled the possibility for targeted treatments may arise.
So far, several ablation procedures have been developed
aiming to ablate a trigger site for initiation of AF or an ar-
rhythmogenic substrate perpetuating AF. The isolation of trig-
gers residing in the pulmonary veins demonstrated to be most
successful in patients with paroxysmal AF. Nonetheless, re-
currences occur frequently especially in patients with persis-
tent AF, suggesting an incomplete eradication, reformation, or
progression of the arrhythmogenic substrate. Other strategies
include the ablation of rotors, ganglionated plexi, and com-
plex fractionated electrograms [8–10]. However, these thera-
pies have similar, limited success rates and there are no guide-
lines as to which strategy to choose for an individual patient.
The present study has been designed to identify the arrhyth-
mogenic substrate in individual AF patients with the use of a
high-resolution epicardial mapping approach. In previous
studies, high-resolution epicardial mapping of patients with
Wolf-Parkinson-White syndrome or longstanding persistent
AF demonstrated to be a valuable tool in discriminating be-
tween patients [11, 12]. However, mapping was performed at
only three locations and in a limited number of patients with a
variety of heart disorders. In this study, subjects are catego-
rized according to the underlying heart disorder(s) and predis-
position for developing spontaneous episodes of AF before or
after cardiac surgery and epicardial mapping will be per-
formed of the entire epicardial surface [13, 14]. The electro-
physiological properties of the atria will be analyzed aiming to
find the arrhythmogenic substrate and to contribute to the
current knowledge of the pathophysiology of AF.
Methods
Study Population
All patients 18 years and older, with structural or coronary
heart disease scheduled for elective cardiac surgery will be
asked to participate. Patients who have a high-risk of compli-
cations during surgery or hemodynamic instability by induc-
ing AF such as Wolff-Parkinson-White syndrome, poor left
ventricular function (<40 %), presence of assist devices, he-
modynamic instability, usage of inotropic agents, and kidney
or liver failure are excluded from this study. Furthermore,
patients with medical histories predisposing them for adhe-
sions making epicardial mapping unfeasible or presence of
an iatrogenically altered atrial electrophysiology such as prior
radiation of the chest for malignancies, redo-cardiac surgery,
paced atrial rhythms, and prior ablative therapy in the atria are
excluded as well. Each patient, prior to enrolling in the study,
will be provided with a written explanation of the study pro-
cedure together with an assessment of risks in participating in
the study. Patients will be enrolled after the written informed
consent form is signed. After enrollment patients are assigned
to a group according to the underlying heart disease and
whether their medical history includes AF. These groups con-
sist of the following surgical procedures: coronary artery by-
pass grafting (CABG), mitral valve surgery, aortic valve sur-
gery, mitral valve surgery with CABG, aortic valve surgery
with CABG, and congenital heart surgery. Each of these
groups are divided into separate groups for patients with and
without prior AF episodes. Figure 1 demonstrates the inclu-
sion and following procedures for patients participating in the
study.
Study Procedure
Epicardial mapping is performed during open heart surgery
[13]. Patients will be under general anesthesia and vital signs
will be monitored continuously throughout the procedure.
Mapping will be performed before going on extracorporeal
circulation, during sinus rhythm, and (induced) AF. AF is
induced by fixed rate pacing at the right atrial appendage with
a pulse width of 2 ms delivered by temporary pacemaker
wires. Pacing bursts will start at a rate of 250 bpm and will
be increased with steps of 50 bpm each time AF is not induced
after 3 attempts. If AF is not induced at a pacing rate of
400 bpm or loss of capture occurs, attempts will be terminated.
As AF is induced it may terminate spontaneously, otherwise,
if an induced arrhythmia sustains after the mapping procedure,
electrical cardioversion will be performed immediately after-
wards. If a patient is in AF at the onset of the mapping proce-
dure, mapping will be performed during AF and during sinus
rhythm after electrical cardioversion if there is no atrial throm-
bus present on transesophageal echocardiogram.
Epicardial mapping of the right and left atria will be per-
formed using a custom-made electrode array (192 electrodes,
diameter 0.45 mm, 2-mm inter-electrode distance; GS Swiss,
Küssnacht, Swiss). All electrograms recorded by the electrode
are stored on hard disk after amplification (gain 1000), filtering
(bandwidth 0.5–400 Hz), sampling (1 KHz) and analogue to
digital conversion (16 bits). An indifferent electrode is attached
to a steal wire fixed in subcutaneous tissue and a reference
signal is attached to the right atrium. In addition, a ventricular
surface electrocardiogram (ECG) is recorded simultaneously.
Signals will be recorded at 9 right and left atrial sites during
sinus rhythm for 5 s per site and during (induced) AF for 10 s
per site. Mapping is initiated at the lower right atrium and is
proceeded upwards over the right atrial appendage. Thereafter,
the left atrium will be mapped starting between the pulmonary
veins and will continue along the atrioventricular groove from
the lower pulmonary veins to the left atrial appendage and
finally at the roof of the left atrium for Bachmann’s bundle.
The mapping positions are demonstrated on a 3D model in
the online Supplementary Video (1). The entire mapping
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procedure will not prolong the surgical procedure by more than
10–15 min [13].
Follow-up and Study Endpoint
The postoperative heart rhythm is continuously monitored
until hospital discharge and rhythm registrations will be
stored in order to determine the incidence of early postop-
erative AF. After discharge, all patients will be scheduled
to visit an out-patient clinic, two times during the first year
and thereafter once a year during the following 4 years.
Clinical history focused on tachyarrhythmias will be taken
and a surface ECG will be made. If indicated, a 24-h Holter
recording will be performed. If patients, for any reason, are
unable to visit the out-patient clinic, follow-up is done by
telephone. In the event that documented rhythm disorders
have occurred, records will be requested from the visited
hospital. The main endpoint of the study is reached when
persistent AF develops.
Data and Statistical Analysis
Local activation times of the recorded atrial signals will be
marked, from which color-coded activation and wave maps
will be reconstructed by custom-made software which has
previously been described in more detail [11]. Data exclu-
sion criteria include progressive in- or decrease in AF cycle
length (AFCL) between sequential recordings (recorded
via the reference signal) indicated by an approximately
two times in- or decrease in AFCL, recordings of other
rhythms than sinus rhythm or AF, or ≥50 % of missing
recording data. Data analysis and the criteria for data in-
clusion are demonstrated in Fig. 2. Electrophysiological
parameters that will be derived include conduction veloci-
ty, incidence of conduction block, number of fibrillation
waves, incidence of epicardial breakthroughs, AFCL,
dominant frequency, electrogram voltage (the amplitude
of the highest deflection in case of fractionation) and frac-
tionation [11, 12]. For analysis, the electrodes of the map-
ping array are assigned to quadrants of 1 cm2. The vari-
ables will consist of averaged values or the percentage of
occurrence/incidence for each quadrant. Figure 3 illustrates
the construction of an activation map during sinus rhythm,
quadrant partition, and its conversion into various param-
eters of all atrial sites. Figure 4 shows a wave map during
AF and the variables that will be analyzed. Furthermore,
rotor occurrence and the relation between patterns of acti-
vation, fractionation, fibrillation intervals, conduction ab-
normalities, and voltage will be studied and compared be-
tween the different atrial sites, atrial rhythms, and patient
groups. Rotors will be defined as a wave of excitation
rotating around a phase singularity for one or more cycles
[15] and analyzed by determining the dominant frequen-
cies at each recording site in order to identify high-to-low
Fig. 1 Flow-chart of patient inclusion and following study procedures.
After enrollment, patients are assigned to 1 of 12 groups for data analysis
according to the presence of previous atrial fibrillation (AF) occurrence
and the type of surgery that will be performed (i.e., underlying heart
disease). Subsequently, all patients are mapped during surgery and
continuously monitored after surgery to detect postoperative AF. During
the 5-year follow-up (FU), the additional tests consist of an electrocar-
diogram (ECG) and Holter monitoring when patients indicate symptoms
suspected of AF. ICF informed consent form, CABG coronary artery
bypass grafting, MV mitral valve surgery, AV aortic valve surgery, CHD
congenital heart disease
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frequency gradients and determination of the degree of
linking of fibrillation waves, indicative of repetitive
patterns of activation. Linear regression analysis and
paired Student’s t test will be used to compare various
Fig. 2 Flow-chart of data evaluation. Atrial fibrillation (AF) data from
patients that were reinduced >2 times is excluded. Custom-made software
detects atrial markings with the presented properties for sinus rhythm (SR)
and AF. If ≥50% of a 1 cm2 quadrant is not marked, this quadrant will be
excluded from further analysis. Rhythm evaluation is performed with use
of the activation and wave maps, and the position in SR is evaluated for
overlap with a total SR map constructed with use of the reference signal.
All data is manually checked, from which the parameters are derived
afterwards
Fig. 3 Left: activation map constructed during sinus rhythm. The atrial
complexes (A) of all 192 recordings are automatically detected and
marked at the steepest deflection. The electrode with the earliest atrial
marking is set at time (T) 0. Activation times of the other electrodes are in
reference to T0. Isochrones are set at 5 ms intervals after T0. The black/
white arrow illustrates the direction of conduction. Conduction block
(<18 cm/s) is represented by thick black lines. V ventricular complex.
Right: The mapping surface is divided into quadrants and parameters
such as block %, and mean voltage are determined for each quadrant of
each mapping location (total: 36 quadrants). LA left atrium, PV
pulmonary veins, BB Bachmann’s bundle, RA right atrium
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electrophysiological parameters between different sites and
different atrial rhythms. Unpaired Student’s t test will be
used to compare various electrophysiological parameters
between patient groups.
The present study is the first that will explore the value
of various parameters in discriminating the arrhythmogenic
substrate of different patients with AF. We aim for a sample
of (at least) 50 subjects in each group for the following
reasons. First, our initiative should be considered as an
exploratory study. We want to obtain early results in a
relative limited number of patients, which will provide a
basis for future (in depth) investigations. Therefore, we
accept that our study will be underpowered to draw defi-
nite conclusions with good precision. Additionally, it is
relevant to obtain estimates with sufficient precision, also
in early, hypothesis generating studies such as ours. In the
binomial distribution, a probability of an observation of
50 % is achieved with the greatest measurement error.
Taking that probability as the ‘worst case’, in a dataset of
50 patients, the 95 % confidence intervals (CIs) around an
observation would be ±14 %. In the 6*50 = 300 AF patients
together, the 95 % CIs would be ±6 %. We consider these
precisions acceptable for this exploratory study that will,
hopefully, discover parameters that may be used in future
studies to discriminate between AF patients with different
underlying heart diseases.
Ethics
The study protocol was approved in February 2010 by the
Medical Ethics Committee (2010–054) in the Erasmus
Medical Center, Rotterdam, The Netherlands.
Discussion
Study Population and Mapping Sites
Previous epicardial mapping studies for AF were per-
formed in small numbers of patients and at only a few atrial
sites or with a low resolution [11, 12, 16–19]. The present
study is the first to perform intra-operative high-resolution
epicardial mapping in a large number of patients and en-
ables analyses between patients with different heart dis-
eases. In addition, all sites of both the right and the left
atrium accessible from the epicardial side are mapped in-
cluding Bachmann’s bundle. Bachmann’s bundle might
have an important role in the pathophysiology of AF
[20]. By mapping the entire surface of both atria there is
an increased chance of finding the arrhythmogenic sub-
strate, which might be located in different atrial regions
among AF patients.
Fig. 4 Left: wavemap during atrial fibrillation at the right atrial free wall.
A total of 5 waves activate the recording area in 41ms; 3 peripheral waves
(black arrows) and 2 initiate at epicardial breakthroughs (white star and
white arrows). Black lines between electrodes indicate conduction block
(<18 cm/s). Isochrones of waves are set at steps of 5 ms after T0.
Parameters derived from the wavemap include a number of epicardial
breakthroughs, waves, and conduction velocity. Right: Examples of
corresponding electrograms are shown. The parameters that will be
derived from electrograms include atrial fibrillation cycle length
(AFCL), fractionation, and voltage
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The Arrhythmogenic Substrate in AF
The heterogeneous nature in which AF presents and the fre-
quently failing AF treatments so far, demonstrate the impor-
tance for an individualized strategy in the treatment of AF. The
first step is a better understanding of the pathophysiology
underlying initiation and perpetuation of AF. The focus for
initiation of AF often originates in the pulmonary veins and
Moe et al. described the concept of self-sustaining fibrillatory
waves responsible for perpetuation of AF [21, 22]. However,
recurrences of persistent AF after successful isolation of the
pulmonary veins cannot be explained by these concepts alone.
The occurrence of longitudinal dissociation during AF was
demonstrated later on and showed to be most prominent in
persistent AF [11]. Furthermore, focal fibrillation waves
emerging within the recording area, referred to as epicardial
breakthroughs, occur much more frequently during persistent
AF than during acute AF [12], as well as drivers such as rotors
and focal sources [23]. These findings suggest that progres-
sive electro-pathological changes within the atria are associat-
ed with persistent AF. Nonetheless, the exact pathophysiolog-
ical changes and locations at which they occur are not yet
known. The underlying diseases most likely initiate different
pathophysiological mechanisms that lead to AF. For example,
valvular disorders give rise to atrial pressure or volume over-
load, coronary artery disease can cause atrial ischemia and
infarction, and congenital heart diseases may also include con-
genital atrial abnormalities. For this reason, the patients in this
study are divided in separate groups according to the under-
lying heart disorders and AF occurrence prior to surgery.
Previous studies have investigated the underlying cause
responsible for perpetuation of AF. Atrial fibrosis has been
suggested to be an important element in the pathophysiology
of AF. There is a significant larger amount of atrial fibrosis
seen in patients with AF [7, 24]. An excessive extracellular
matrix leads to uncoupling of cells and may facilitate inhomo-
geneous conduction, re-entry, and multiple wavelets. MRI or
electro-anatomical voltage mapping can be helpful diagnostic
tools for the determination of degree of fibrosis in AF patients
and identification of areas of fibrosis. However, no association
has been found between the amount of fibrosis and clinical AF
characteristics [7, 24]. Electrical signal conduction involves
processes on a structural, cellular and molecular level, and
these together determine if conduction is altered and AF oc-
curs. Therefore, the arrhythmogenic substrate can probably be
more accurately localized by measuring electrical potentials
and conduction. In the present study, both the recorded extra-
cellular potentials and the spatial domain of the electrograms
enables conversion into specific electrophysiological parame-
ters that could identify areas with conduction abnormalities. If
proven successful, this strategy can be developed into a diag-
nostic tool for each individual AF patient. In addition, current
ablation strategies aimed at identifying and targeting
arrhythmogenic areas are not effective in a large proportion
of patients and might even lead to new arrhythmias [25]. If
patients that can benefit could be selected beforehand, effec-
tiveness of these treatments might improve.
Study Limitations
Currently, epicardial mapping can only be performed during
open-chest cardiac surgery. Therefore, it is not possible to
perform epicardial mapping in patients with nondiseased
hearts. However, with constantly advancing techniques it
may become possible in the future to perform epicardial map-
pings during video-assisted thoracoscopic surgery in patients
without any heart disease. Secondly, although epicardial map-
ping can reach sites endocardial mapping cannot, some sites
are not accessible, for example, the atrial septum. Therefore,
epicardial mapping is not able to analyze conduction in the
entire area of the atria. In addition, recordings are performed
sequentially, as simultaneous high-resolution mapping of the
entire surface is not possible yet with currently available tech-
nical equipment. As time during surgery is limited, mapping is
performed immediately after AF induction or electrical con-
version. Consequently, if a progressive increase, or decrease
in AFCL occurs during the recordings, this data will have to
be excluded [26–28]. General anesthesia may also increase
AFCL [29]. However, the same anesthetic protocol is applied
in all patients and previous studies have shown that there
remain differences in AF between patients despite anesthesia
[11, 12]. Furthermore, recent studies have shown that endo-
epicardial dissociation can occur during AF and might be
associated with persistent AF [30]. This suggests that it is
important to investigate endocardial and epicardial conduction
simultaneously as conduction can be disturbed in all three
dimensions. Finally, there is a small chance asymptomatic
persistent AF episodes may be undetected during follow-up.
The measured incidence of persistent late postoperative AF
may therefore underestimate the true incidence of persistent
late postoperative AF.
Clinical Relevance
This project can provide the tools to discriminate the arrhyth-
mogenic substrate of AF in patients with different heart dis-
eases and is potentially the first step towards a patient-tailored
strategy for the treatment of AF.
Project Status
At present, the inclusion for this study is ongoing. We expect
the data of this project to become available in 2016 or 2017.
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